Puredutide molecular structure
Puredutide molecular structure
Experimental
🏋️Weight Loss

Puredutide

Also known as: LY3541105, GLP-1/Glucagon Dual Agonist

Routes

1 route

Puredutide is an investigational dual GLP-1/glucagon receptor agonist developed by Eli Lilly. Unlike tirzepatide which targets GIP/GLP-1, puredutide combines GLP-1 receptor agonism with glucagon receptor agonism — aiming to enhance energy expenditure through glucagon's thermogenic and lipolytic effects while providing GLP-1-mediated appetite suppression and glycemic control. The glucagon component differentiates puredutide from pure GLP-1RAs by promoting hepatic fat oxidation, increasing energy expenditure, and enhancing amino acid catabolism. This dual mechanism addresses both energy intake (GLP-1) and energy expenditure (glucagon), similar to retatrutide's approach but without the GIP component. Puredutide is in Phase 2 clinical development for obesity and MASH/NASH.

Research Use Only— For educational and research purposes only

Research Applications

Obesity

Phase 2 trials in progress. Targets dual energy balance mechanism.

MASH/NASH

Glucagon-mediated hepatic fat reduction combined with GLP-1 anti-inflammatory effects make this a promising NASH candidate.

Type 2 Diabetes

Being studied with careful monitoring of glycemic balance between GLP-1 (glucose-lowering) and glucagon (glucose-raising) effects.

Mechanism of Action

Puredutide activates both GLP-1R and GCGR. GLP-1R agonism provides glucose-dependent insulin secretion, appetite suppression, and delayed gastric emptying. GCGR agonism enhances hepatic fat oxidation, increases energy expenditure through thermogenesis, and promotes lipolysis. The balance between these agonisms is carefully tuned to maximize metabolic benefit while preventing hyperglycemia.

Biological Pathways

GLP-1R/cAMP for appetite and insulin. GCGR/cAMP/PKA for hepatic lipid oxidation and energy expenditure. AMPK activation. FGF21 upregulation via glucagon signaling.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Typical Dose
3,200 mcg
Dose Range
600 - 4,800 mcg
Frequency
Phase 2 clinical trials: 0.6-4.8 mg SC once weekly with titration
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Investigational compound. Once-weekly subcutaneous injection in clinical trials. Stability data not publicly available.

Side Effects & Precautions

GI effects (nausea, vomiting, diarrhea) expected based on GLP-1R agonism. Potential for hyperglycemia from glucagon component, though balanced by GLP-1 effects. Full safety profile pending clinical trial completion.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Experimental

Investigational — Phase 2 clinical trials. Not approved by any regulatory authority. Early-stage development by Eli Lilly.

Research Studies

GLP-1/Glucagon Dual Agonism for Metabolic Disease

Day JW, Ottaway N, Patterson JT, et al.

Nature Chemical Biology
2009
View Source

Dual Glucagon-GLP-1 Receptor Agonists in Obesity

Ambery P, Parker VE, Sheridan P, et al.

Lancet
2018
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Puredutide.
Open Calculator
Explore More
Explore more peptides in the Weight Loss category and related research.
View Weight Loss Category